BCAB Stock Summary and Trading Ideas (Bioatla | NASDAQ:BCAB)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Bioatla trades on the NASDAQ stock market under the symbol BCAB.

As of December 24, 2025, BCAB stock price climbed to $0.72 with 999,434 million shares trading.

BCAB has a beta of 2.33, meaning it tends to be more sensitive to market movements. BCAB has a correlation of 0.11 to the broad based SPY ETF.

BCAB has a market cap of $42.57 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCAB traded as high as $9.00 and as low as $.24.

The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VTI, VXF.

BCAB has outperformed the market in the last year with a return of +18.5%, while the SPY ETF gained +17.3%. In the last 3 month period, BCAB beat the market returning +24.9%, while SPY returned +4.4%. However, in the most recent 2 weeks BCAB has underperformed the stock market by returning -10.1%, while SPY returned +1.4%.

BCAB support price is $.62 and resistance is $.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.